Ocular mucous membrane pemphigoid

被引：0

作者：

Yaici, R. ^{[1
,2
]}

Roth, M. ^{[1
]}

Geerling, G. ^{[1
]}

机构：

[1] Univ Klinikum Dusseldorf, Klin Augenheilkunde, Dusseldorf, Germany

[2] Univ Klinikum Dusseldorf, Klin Augenheilkunde, Moorenstr 5, D-40225 Dusseldorf, Germany

来源：

OPHTHALMOLOGIE | 2023年 / 120卷 / 07期

关键词：

Symblepharon; Scarring conjunctivitis; Immunosuppression; Autoimmune disease; Inflammation; IMMUNOSUPPRESSIVE THERAPY; EXTRACELLULAR DOMAINS; AUTOANTIBODIES; RITUXIMAB; DISEASE; KERATOPROSTHESIS; CYCLOPHOSPHAMIDE; CONJUNCTIVITIS; INVOLVEMENT; PREVALENCE;

D O I：

10.1007/s00347-023-01880-y

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Mucous membrane pemphigoid refers to a heterogeneous group of autoimmune diseases with subepidermal blister formation that can affect all mucous membranes with varying frequencies. This is a rare disease without any geographic or sexual predisposition that is characterized by recurrent inflammation and progressive scarring. The specific diagnostics can be negative in up to 50% of cases. The diagnosis is predominantly made in patients aged 60-80 years. Ophthalmologists play an important role in the care of affected individuals as the conjunctiva is the second most frequent site of involvement. The treatment is often tedious and primarily consists of long-term systemic immunosuppression.

引用

页码：779 / 790

页数：12

共 50 条

[31] The management of mucous membrane pemphigoid and pemphigus
Knudson, Richelle M.
Kalaaji, Amer N.
Bruce, Alison J.
DERMATOLOGIC THERAPY, 2010, 23 (03) : 268 - 280
[32] Mucous membrane pemphigoid with ocular involvement. Part II: Therapy
Meyer-ter-Vehn, T.
Schmidt, E.
Zillikens, D.
Geerling, G.
OPHTHALMOLOGE, 2008, 105 (04): : 405 - 418
[33] Long-term Results of Therapy with Mycophenolate Mofetil in Ocular Mucous Membrane Pemphigoid
Doycheva, Deshka
Deuter, Christoph
Blumenstock, Gunnar
Stuebiger, Nicole
Zierhut, Manfred
OCULAR IMMUNOLOGY AND INFLAMMATION, 2011, 19 (06) : 431 - 438
[34] Disease Relapse After Drug-Free Remission in Ocular Mucous Membrane Pemphigoid
Shifera, Amde Selassie
Hong, Gloria H.
Khan, Irfan R.
Okeagu, Chinwenwa
Thorne, Jennifer E.
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2021, 223 : 21 - 27
[35] Therapie des okulären SchleimhautpemphigoidsTreatment of ocular mucous membrane pemphigoid
G. Geerling
R. Yaici
M. Roth
Die Ophthalmologie, 2023, 120 (5) : 496 - 501
[36] Diagnostik des okulären SchleimhautpemphigoidsDiagnostics of ocular mucous membrane pemphigoid
Velina Haralanova
Katharina Meier
Uwe Pleyer
Die Ophthalmologie, 2023, 120 (5) : 484 - 495
[37] Mucous membrane pemphigoid: recent advances
Srikumaran, Divya
Akpek, Esen K.
CURRENT OPINION IN OPHTHALMOLOGY, 2012, 23 (06) : 523 - 527
[38] The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement
Ross, A. H.
Jaycock, P.
Cook, S. D.
Dick, A. D.
Tole, D. M.
BRITISH JOURNAL OF OPHTHALMOLOGY, 2009, 93 (04) : 421 - +
[39] Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment
Georgoudis, Panagiotis
Sabatino, Francesco
Szentmary, Nora
Palioura, Sotiria
Fodor, Eszter
Hamada, Samer
Scholl, Hendrik P. N.
Gatzioufas, Zisis
OPHTHALMOLOGY AND THERAPY, 2019, 8 (01) : 5 - 17
[40] Tumor Necrosis Factor-α in Ocular Mucous Membrane Pemphigoid and Its Effect on Conjunctival Fibroblasts
Saw, Valerie P. J.
Dart, Robin J. C.
Galatowicz, Grazyna
Daniels, Julie T.
Dart, John K. G.
Calder, Virginia L.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2009, 50 (11) : 5310 - 5317

← 1 2 3 4 5 →